Delivering
Transformative Talent

The executive search partner to the early-stage biotech sector

Our next event:

BioTrinity | 23rd-24th April 2024 | Convene 133 Houndsditch, London

About us

Precision BioSearch supports early-stage ventures to overcome the challenge of hiring in a fiercely competitive market.  Founded in 2020, we introduce the inspiring leaders and visionary experts in next-generation therapeutics that help companies deliver innovative medicines to patients. Through implementing agile principles, Precision BioSearch works to accelerate business-critical hiring, allowing organisations to scale with speed and confidence.

Jemma Challinor

Jemma has over 16 years’ experience in Executive Search exclusively within the field of therapeutic drug discovery and development.

Malcolm Silander

Malcolm has dedicated his professional career to recruitment within the Life Science sector.

Featured Case Study

LOGO

Malcolm and Jemma were engaged by Camena
Bioscience to help appoint a Non-Executive Chair
following a successful fundraise. We gave them a
challenging brief to ensure that a diverse range of
well-skilled candidates, who would also fit into
Camena’s culture, were considered for role.
The service was excellent from start to finish.
The process was efficient, the shortlist of candidates
impressive and we were delighted with the outcome
of the search. We’d highly recommend Precision
BioSearch and look forward to working with
Malcolm and Jemma again in the future.

Person Name, Job Title

Role

Role answer

Stage

stage answer

Science

science answer

Investor

investor answer

Project

project answer

Process

process answer

Result

result answer

Testimonials

Access to industry recognised leaders across the value chain from R&D to commercialisation

C LEVEL
FUNCTIONAL HEADS
BOARD

Biology, Chemistry, Translational Science, Clinical Research, Medical, Regulatory, Quality, Business Development, Operations, Finance

Case Study

“Precision BioSearch impressed us with their ability to attract outstanding Executives in the Cell and Gene field.”

Jonathan Pheasant
Snr Director, People

  • Role:

    CBO, COO, VP Quality

  • Stage:

    Seed stage

  • Science:

    Gene & cell therapy; CDMO

  • Investor:

    Monograph Capital – Tim Funnell, Partner

  • Investor:

    Monograph Capital – Tim Funnell, Partner

  • Project:

    Build the Leadership Team of a stealth mode, pan-European CDMO in advance of company launch: CBO to support BD and fundraising; COO to lead company and site build; VP Quality to ensure GxP standards.

  • Process:

    During the fundraising cycle, appoints were made of a first-time CBO, experienced COO and experienced VPQ.

  • Result:

    The successful acquisition of Freeline Tx’s German subsidiary and raise of $132.5M Series A, led by Petrichor and syndicated with Abingworth.

Case Study

ascend
  • Role:

    CBO, COO, VP Quality

  • Stage:

    Seed stage

  • Science:

    Gene & cell therapy; CDMO

  • Investor:

    Monograph Capital – Tim Funnell, Partner

  • Investor:

    Monograph Capital – Tim Funnell, Partner

  • Project:

    Build the Leadership Team of a stealth mode, pan-European CDMO in advance of company launch: CBO to support BD and fundraising; COO to lead company and site build; VP Quality to ensure GxP standards.

  • Process:

    During the fundraising cycle, appoints were made of a first-time CBO, experienced COO and experienced VPQ.

  • Result:

    The successful acquisition of Freeline Tx’s German subsidiary and raise of $132.5M Series A, led by Petrichor and syndicated with Abingworth.